Відмінності між версіями «Le disease in peripheral blood or bone marrow even when»
м |
м |
||
| Рядок 1: | Рядок 1: | ||
| − | + | Le illness in peripheral blood or bone marrow even when very sensitive immunophenotypic or molecular techniques are utilised to look for [http://www.medchemexpress.com/Betulin.html Trochol site] residual disease. Santacruz et al.deletion have a higher probability of remaining MRD-positive soon after therapy in comparison with sufferers with out this chromosome abnormality.18 For all these motives, present suggestions for the management of individuals with CLL advise MRD assessment only inside clinical trials with "curative intention".36 With all this facts in thoughts, we retrospectively evaluated the influence of MRD on the outcome of individuals with CLL receiving any front-line therapy within the context of a very detailed prognostic evaluation, including recently described recurrent gene mutations.survival and all round survival were calculated using a landmark analysis. All calculations had been performed making use of either SPSS, version 18.0, or R, version 3.0.1. Two-sided P values 0.05 have been deemed statistically important. A detailed explanation on the statistical approaches is accessible inside the On the web Supplement.Outcomes Baseline characteristicsThe median age on the complete cohort was 58 years (range, 27-93 years), as well as the percentage of patients older than 70 years was 22 . As outlined by D ner's hierarchical model, 17/221 (8 ) and 40/221 (18 ) sufferers had 17p deletion and 11q deletion, respectively.Le disease in peripheral blood or bone marrow even when very sensitive immunophenotypic or molecular strategies are employed to appear for residual disease. These sufferers are considered to possess accomplished a minimal residual disease (MRD) unfavorable status.17-20 Various phase II trials have demonstrated that patients reaching MRD negativity possess a signif-icantly longer survival than people that remain MRD optimistic, and this really is true for individuals treated with traditional chemotherapy,21,22 monoclonal antibodies,23 chemoimmunotherapy,24 or stem cell transplantation.25,26 Additionally, a phase III trial performed by the German CLL Study Group (GCLLSG) lately revealed that patients acquiring MRD negativity had significantly longer progression-free and overall survivals, irrespectively with the treatment received.18 Regrettably, nonetheless, a few of these research were flawed by inappropriate statistical evaluation, particularly the measurement of time-to-event outcomes from remedy initiation.27 Additionally, there are several caveats towards the use of MRD evaluation in patients with CLL.28 Initially, CLL remains incurable and no less than 30 of individuals who accomplish MRD negativity just after front-line therapy with fludarabine-cyclophosphamide (FC) or rituximab-FC sooner or later expertise a illness relapse within 5 years.18 Secondly, unlike the circumstance in acute promyelocytic leukemia or chronic myeloid leukemia,29,30 there is certainly no formal proof of a therapeutic advantage of re-treatment upon documentation of MRD positivity immediately after an initial MRD-negative response when compared with treatment at the time of clinical relapse. The truth is, extremely couple of studies have demonstrated a clear advantage from MRD eradication or consolidation therapy in CLL,31,32 and a few of your approaches tested, although successful, resulted in substantial toxicity.33-35 Thirdly, it could be argued that MRD assessment is just a surrogate for evalution of other adverse prognostic markers due to the fact, for instance, individuals using a 17p014 Ferrata Storti Foundation. This is an open-access paper. doi:ten.3324/haematol.2013.099796 The on the web version of this short article features a Supplementary Appendix. Manuscript received on October 17, 2013. | |
Версія за 07:54, 1 лютого 2018
Le illness in peripheral blood or bone marrow even when very sensitive immunophenotypic or molecular techniques are utilised to look for Trochol site residual disease. Santacruz et al.deletion have a higher probability of remaining MRD-positive soon after therapy in comparison with sufferers with out this chromosome abnormality.18 For all these motives, present suggestions for the management of individuals with CLL advise MRD assessment only inside clinical trials with "curative intention".36 With all this facts in thoughts, we retrospectively evaluated the influence of MRD on the outcome of individuals with CLL receiving any front-line therapy within the context of a very detailed prognostic evaluation, including recently described recurrent gene mutations.survival and all round survival were calculated using a landmark analysis. All calculations had been performed making use of either SPSS, version 18.0, or R, version 3.0.1. Two-sided P values 0.05 have been deemed statistically important. A detailed explanation on the statistical approaches is accessible inside the On the web Supplement.Outcomes Baseline characteristicsThe median age on the complete cohort was 58 years (range, 27-93 years), as well as the percentage of patients older than 70 years was 22 . As outlined by D ner's hierarchical model, 17/221 (8 ) and 40/221 (18 ) sufferers had 17p deletion and 11q deletion, respectively.Le disease in peripheral blood or bone marrow even when very sensitive immunophenotypic or molecular strategies are employed to appear for residual disease. These sufferers are considered to possess accomplished a minimal residual disease (MRD) unfavorable status.17-20 Various phase II trials have demonstrated that patients reaching MRD negativity possess a signif-icantly longer survival than people that remain MRD optimistic, and this really is true for individuals treated with traditional chemotherapy,21,22 monoclonal antibodies,23 chemoimmunotherapy,24 or stem cell transplantation.25,26 Additionally, a phase III trial performed by the German CLL Study Group (GCLLSG) lately revealed that patients acquiring MRD negativity had significantly longer progression-free and overall survivals, irrespectively with the treatment received.18 Regrettably, nonetheless, a few of these research were flawed by inappropriate statistical evaluation, particularly the measurement of time-to-event outcomes from remedy initiation.27 Additionally, there are several caveats towards the use of MRD evaluation in patients with CLL.28 Initially, CLL remains incurable and no less than 30 of individuals who accomplish MRD negativity just after front-line therapy with fludarabine-cyclophosphamide (FC) or rituximab-FC sooner or later expertise a illness relapse within 5 years.18 Secondly, unlike the circumstance in acute promyelocytic leukemia or chronic myeloid leukemia,29,30 there is certainly no formal proof of a therapeutic advantage of re-treatment upon documentation of MRD positivity immediately after an initial MRD-negative response when compared with treatment at the time of clinical relapse. The truth is, extremely couple of studies have demonstrated a clear advantage from MRD eradication or consolidation therapy in CLL,31,32 and a few of your approaches tested, although successful, resulted in substantial toxicity.33-35 Thirdly, it could be argued that MRD assessment is just a surrogate for evalution of other adverse prognostic markers due to the fact, for instance, individuals using a 17p014 Ferrata Storti Foundation. This is an open-access paper. doi:ten.3324/haematol.2013.099796 The on the web version of this short article features a Supplementary Appendix. Manuscript received on October 17, 2013.
